PRP19A Antibody

What is PRP19 (PRPF19) and why is it important in cellular functions?

PRP19, also known as Pre-mRNA Processing Factor 19 (PRPF19), is a multifunctional protein involved in several critical cellular processes. It plays essential roles in pre-mRNA splicing as part of the NineTeen Complex (NTC), DNA damage response pathways, and ubiquitin-mediated protein degradation. The importance of PRP19 stems from its central position at the intersection of RNA processing and genome stability mechanisms . In research contexts, PRP19 antibodies are valuable tools for investigating these fundamental cellular processes, particularly in cancer research where aberrant RNA processing is frequently observed. The protein contains distinct functional domains that enable its diverse cellular roles, making it an important target for studying disease mechanisms related to splicing defects and genomic instability .

What are the most appropriate applications for PRP19A antibody in molecular biology research?

PRP19A antibodies are versatile research tools applicable across multiple experimental platforms. Based on validated research applications, these antibodies are primarily used in Western Blotting (WB) for protein expression analysis, Immunohistochemistry (IHC) for tissue localization studies, and Immunoprecipitation (IP) for protein-protein interaction investigations . For researchers investigating splicing mechanisms, PRP19A antibodies can effectively visualize nuclear speckles where splicing occurs. Additionally, these antibodies have proven valuable in chromatin immunoprecipitation (ChIP) experiments examining PRP19's role in transcription-coupled DNA repair mechanisms, though this application requires careful optimization of crosslinking conditions. When selecting application parameters, researchers should consider that polyclonal PRP19A antibodies typically show higher sensitivity but may display batch-to-batch variation, while monoclonal variants offer improved reproducibility across experiments .

How do I determine the optimal working dilution for PRP19A antibody in Western Blotting experiments?

Determining the optimal working dilution for PRP19A antibody requires a systematic titration approach. For Western Blotting applications, begin with a dilution series ranging from 1:500 to 1:5000 using a consistent amount of protein lysate (typically 20-30μg) from a cell line known to express PRP19 (such as HeLa or HEK293T cells). The commercially available PRP19 antibody (ABIN6146256) recognizing amino acids 127-416 typically performs optimally at dilutions between 1:1000 and 1:2000 for Western Blotting .

When optimizing, consider these methodological parameters:

• Blocking solution composition (5% non-fat milk vs. BSA)

• Incubation time and temperature (overnight at 4°C vs. 1-2 hours at room temperature)

• Washing stringency (TBST concentration and number of washes)

• Detection method sensitivity (chemiluminescence vs. fluorescence)

Document signal-to-noise ratio at each dilution and select the concentration that provides clear specific bands at approximately 55kDa (the expected molecular weight for PRP19) while minimizing background. Verification with positive and negative control samples is essential for confirming specificity .

How does epitope selection influence the specificity and utility of PRP19A antibodies in research applications?

Epitope selection represents a critical determinant of PRP19A antibody specificity and experimental utility. PRP19A antibodies targeting different epitopes demonstrate distinct performance characteristics across applications. The ABIN6146256 antibody recognizes amino acids 127-416, which encompasses the U-box domain and WD40 repeats of the PRP19 protein . This epitope selection has specific research implications:

Antibodies targeting the N-terminal region (amino acids 1-90) typically show higher specificity for distinguishing between splice variants but may demonstrate reduced sensitivity in certain applications like IHC. Conversely, antibodies recognizing the middle region (amino acids 127-416) provide robust performance across multiple applications (WB, IHC, IP) due to the accessibility of this epitope in both native and denatured protein conformations .

For researchers investigating PRP19's protein-protein interactions, antibodies targeting the WD40 repeat region (located within amino acids 127-416) are particularly valuable as they can detect protein complexes while minimizing interference with binding partners. When investigating post-translational modifications, researchers should select antibodies whose epitopes do not include the modification sites of interest to avoid potential masking effects .

The following table summarizes how epitope selection influences application performance:

Researchers should carefully align epitope selection with their specific experimental goals to maximize research outcomes .

What cross-reactivity patterns should researchers be aware of when using PRP19A antibodies across species?

Cross-reactivity patterns of PRP19A antibodies represent an important consideration for comparative studies across species. The ABIN6146256 PRP19 antibody demonstrates confirmed cross-reactivity with human, mouse, and rat PRP19 proteins . This cross-reactivity profile can be attributed to high sequence conservation in the epitope region (amino acids 127-416) across these mammalian species.

Researchers should be aware of several important considerations when leveraging this cross-reactivity:

The high degree of conservation in PRP19 makes these antibodies valuable tools for evolutionary studies of RNA processing mechanisms, but careful validation remains essential when extending beyond confirmed reactive species .

How can researchers distinguish between different isoforms of PRP19 using available antibodies?

Distinguishing between PRP19 isoforms requires strategic antibody selection and complementary experimental approaches. The human PRPF19 gene can produce multiple transcript variants through alternative splicing, resulting in protein isoforms with distinct functional properties. Available antibodies offer different capabilities for isoform discrimination:

Antibodies targeting amino acids 127-416 (like ABIN6146256) recognize a region common to most PRP19 isoforms, providing broad detection but limited isoform discrimination . For isoform-specific detection, researchers should consider:

• Epitope-based strategy: Select antibodies targeting unique sequence regions present only in specific isoforms. Antibodies recognizing the N-terminal region (amino acids 1-90) may provide better isoform discrimination than those targeting conserved functional domains.

• Size-based discrimination: Optimize Western blot conditions to clearly resolve small molecular weight differences between isoforms. This requires:

  • Using lower percentage (8-10%) polyacrylamide gels

  • Extended run times to maximize separation

  • Precision protein standards with closely spaced markers

• Two-dimensional electrophoresis: Combining isoelectric focusing with SDS-PAGE enables separation based on both molecular weight and charge differences between isoforms, which can be subsequently detected with PRP19A antibodies.

• Validation approach: Confirm isoform identity through:

  • RNA interference using isoform-specific siRNAs

  • Recombinant expression of specific isoforms as positive controls

  • Mass spectrometry validation of bands/spots recognized by the antibody

When absolute isoform specificity is required, researchers may need to employ complementary molecular techniques such as RT-PCR with isoform-specific primers alongside immunological detection methods .

What are the optimal sample preparation protocols for detecting PRP19 in different cellular compartments?

Detecting PRP19 across cellular compartments requires tailored sample preparation protocols that preserve compartment-specific localization while maximizing extraction efficiency. PRP19 functions in multiple cellular locations including the nucleus (as part of the spliceosome), cytoplasm, and potentially mitochondria. Effective protocols must account for these diverse localizations.

For nuclear fraction analysis:

• Employ gentle hypotonic lysis (10mM HEPES pH 7.9, 1.5mM MgCl₂, 10mM KCl, 0.5mM DTT)

• Separate nuclei by centrifugation (3000×g, 10 minutes)

• Extract nuclear proteins using high-salt buffer (20mM HEPES pH 7.9, 25% glycerol, 420mM NaCl, 1.5mM MgCl₂, 0.2mM EDTA)

• Include protease inhibitors and phosphatase inhibitors throughout

For cytoplasmic fraction analysis:

• Collect the supernatant from the nuclear isolation step

• Clear by centrifugation (10,000×g, 15 minutes)

• Precipitate proteins using trichloroacetic acid if concentration is necessary

For whole cell analysis:

• Use RIPA buffer extraction (150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris pH 8.0)

• Sonicate briefly to shear DNA and release nuclear proteins

• Clear lysates by centrifugation (14,000×g, 15 minutes)

Critical considerations include:

• Phosphatase inhibitors are essential as PRP19 is subject to regulatory phosphorylation

• Sample heating should be limited to 70°C for 5 minutes to prevent aggregation of WD40 domain-containing proteins

• Fresh samples typically yield superior results compared to frozen-thawed specimens

For immunofluorescence detection of PRP19 in intact cells, 4% paraformaldehyde fixation followed by 0.1% Triton X-100 permeabilization provides optimal epitope preservation while allowing antibody accessibility to nuclear PRP19 .

How can researchers validate the specificity of PRP19A antibody signals in their experimental systems?

Validating PRP19A antibody specificity requires implementing multiple complementary approaches to confirm signal authenticity. Comprehensive validation strategies should incorporate:

• Genetic validation methods:

  • siRNA or shRNA knockdown of PRP19 should demonstrate corresponding reduction in antibody signal

  • CRISPR/Cas9-mediated knockout cell lines provide definitive negative controls

  • Overexpression of tagged PRP19 should show corresponding signal increase and co-localization with antibody staining

• Biochemical validation approaches:

  • Peptide competition assays using the immunizing peptide (amino acids 127-416) should abolish specific binding

  • Western blot analysis should demonstrate a predominant band at the expected molecular weight (~55kDa)

  • Immunoprecipitation followed by mass spectrometry can confirm antibody captures the intended target

• Multiple antibody validation:

  • Compare signals from at least two antibodies targeting different PRP19 epitopes

  • Correlation between antibodies targeting the same protein but different epitopes strengthens validity

• Biologically relevant controls:

  • Include cell types or tissues with known high and low PRP19 expression

  • Verify subcellular localization patterns match known distribution (primarily nuclear with nucleolar exclusion)

  • Confirm expected changes during biological processes (e.g., increased nuclear concentration during active transcription)

• Signal specificity metrics:

  • Calculate signal-to-noise ratios across different antibody concentrations

  • Document absence of signal in negative control samples

  • Verify signal increases linearly with increasing protein concentration in quantitative applications

Implementing these validation approaches provides a robust framework for confirming PRP19A antibody specificity, enhancing experimental reliability and reproducibility .

What strategies can minimize batch-to-batch variation when using PRP19A antibodies in longitudinal studies?

Minimizing batch-to-batch variation in PRP19A antibody performance for longitudinal studies requires implementing systematic standardization procedures throughout the experimental timeline. Researchers conducting extended studies should employ the following strategies:

• Antibody procurement and storage standardization:

  • Purchase sufficient antibody from a single production lot for the entire study duration

  • Aliquot antibodies in single-use volumes to minimize freeze-thaw cycles

  • Maintain consistent storage conditions (-20°C or -80°C as recommended)

  • Document lot numbers and certificate of analysis information for each batch

• Internal reference standardization:

  • Create a large pool of positive control lysate (e.g., HeLa cells) and aliquot for use across the study

  • Include this reference standard in every experiment as an internal calibrator

  • Calculate a normalization factor based on reference standard signal intensity

  • Apply this normalization factor to experimental samples to adjust for batch effects

• Validation panel implementation:

  • Develop a panel of 3-5 samples spanning the expected signal range

  • Test each new antibody batch against this panel before experimental use

  • Establish acceptance criteria for batch-to-batch correlation coefficients (r² > 0.90)

  • Retain validation panel data to track antibody performance over time

• Protocol standardization measures:

  • Create detailed standard operating procedures for all experimental steps

  • Standardize key reagents (blocking solutions, detection systems) across experiments

  • Maintain consistent incubation times and temperatures

  • Utilize automated systems where possible to reduce operator variability

• Data normalization approaches:

  • Employ loading controls appropriate for the subcellular fraction being analyzed

  • Consider dual normalization to both loading controls and internal reference standards

  • Document raw and normalized values to enable retrospective analyses

These comprehensive strategies significantly reduce technical variation in longitudinal studies, ensuring that observed differences reflect true biological changes rather than methodological inconsistencies .

How can researchers effectively use PRP19A antibodies to investigate protein-protein interactions in splicing complexes?

Investigating PRP19A protein-protein interactions within splicing complexes requires specialized approaches that preserve complex integrity while enabling specific detection. PRP19 functions as part of the NineTeen Complex (NTC) that associates with the spliceosome during activation. Researchers can employ several advanced strategies:

• Co-immunoprecipitation optimization:

  • Use gentle lysis conditions (150mM NaCl, 0.5% NP-40, 50mM Tris pH 7.5) to preserve native complexes

  • Validate PRP19A antibody (ABIN6146256) efficiency in IP using Western blot confirmation

  • Consider directed IP against epitopes (amino acids 127-416) that don't interfere with complex formation

  • Implement a two-step cross-linking approach using formaldehyde (0.1%, 10 minutes) followed by DSS (2mM, 30 minutes) to stabilize transient interactions

• Proximity ligation assay (PLA) application:

  • Combine PRP19A antibody with antibodies against suspected interacting partners

  • PLA generates fluorescent signals only when proteins are within 40nm proximity

  • Quantify interaction signals in different cellular compartments or conditions

  • This approach is particularly valuable for detecting interactions that may be lost during extraction

• Chromatin immunoprecipitation (ChIP) for co-transcriptional splicing:

  • Optimize crosslinking conditions (1% formaldehyde, 10 minutes) to capture PRP19 association with nascent transcripts

  • Use sonication conditions that preserve large ribonucleoprotein complexes

  • Perform sequential ChIP with RNA polymerase II antibodies followed by PRP19A antibody

  • Include RNase treatment controls to distinguish RNA-dependent interactions

• Mass spectrometry-based interactome analysis:

  • Perform PRP19A immunoprecipitation under varying stringency conditions

  • Analyze precipitated complexes using liquid chromatography-tandem mass spectrometry

  • Compare interactome profiles under different cellular conditions (e.g., DNA damage response)

  • Validate key interactions using reciprocal co-immunoprecipitation

These methods can be employed complementarily to build comprehensive interaction maps of PRP19 within different cellular contexts and functional states .

What factors influence the correlation between PRP19 mRNA and protein levels detected by antibodies in research samples?

The correlation between PRP19 mRNA and protein levels involves complex regulatory mechanisms that must be considered when interpreting research findings. The relationship between transcript and protein abundance is influenced by multiple factors that can lead to apparent discrepancies in experimental results.

RNA-protein correlation for PRP19 is subject to several key influencing factors:

• Antibody reliability impact:

  • Research demonstrates that antibody reliability significantly influences observed mRNA-protein correlations in tumor cohorts

  • High-reliability antibodies like those targeting the middle region of PRP19 (amino acids 127-416) typically show stronger mRNA-protein correlations than less reliable antibodies

  • In reverse phase protein arrays (RPPA), approximately 25% of antibodies demonstrate reduced reliability, potentially confounding correlation analyses

• Post-transcriptional regulation:

  • PRP19 mRNA is subject to extensive alternative splicing, generating protein isoforms that may not be equally detected by all antibodies

  • miRNA regulation may selectively suppress translation of PRP19 transcripts under specific conditions

  • RNA stability factors can lead to discordant half-lives between transcript and protein

• Post-translational modifications:

  • Ubiquitination (PRP19 itself has E3 ubiquitin ligase activity)

  • Phosphorylation during cell cycle progression and DNA damage response

  • These modifications can affect antibody epitope recognition and protein stability

• Temporal dynamics:

  • Protein synthesis and degradation rates may create time-shifted correlations

  • PRP19 protein demonstrates a relatively long half-life (>24 hours) compared to its mRNA

  • This temporal offset necessitates time-course analyses for accurate correlation assessment

• Subcellular localization effects:

  • Nuclear sequestration or translocation can affect apparent whole-cell protein levels

  • Compartment-specific degradation mechanisms may operate independently of transcription rates

Researchers should consider these factors when designing experiments examining PRP19 expression and implement controls to distinguish biological regulation from technical artifacts. Multiple measurement methods and careful statistical analysis are recommended to establish reliable correlations .

What are the common pitfalls in PRP19A antibody-based research and how can they be overcome?

• Epitope masking due to protein interactions:

  • Problem: PRP19's involvement in protein complexes can obscure antibody epitopes

  • Solution: Use multiple antibodies targeting different regions; employ denaturing conditions for Western blotting; optimize epitope retrieval for IHC (citrate buffer pH 6.0, 20 minutes)

• Post-translational modification interference:

  • Problem: Phosphorylation within the epitope region (amino acids 127-416) can alter antibody binding

  • Solution: Treat samples with phosphatase before analysis; select antibodies whose epitopes avoid major modification sites; compare results with phospho-specific antibodies

• Cross-reactivity with structural homologs:

  • Problem: WD40 repeat domains exhibit structural conservation that may lead to cross-reactivity

  • Solution: Validate specificity using knockout/knockdown controls; perform peptide competition assays; verify single bands of appropriate molecular weight

• Isoform-specific detection limitations:

  • Problem: Alternative splicing generates PRP19 variants that standard antibodies may not distinguish

  • Solution: Use isoform-specific antibodies when available; complement with RT-PCR for isoform expression; employ 2D electrophoresis to separate variants

• Fixation-dependent epitope alteration in microscopy:

  • Problem: Common fixatives can alter conformation of the WD40 repeat structure

  • Solution: Compare multiple fixation protocols (PFA, methanol, glutaraldehyde); validate staining patterns across fixation methods; use live-cell imaging with fluorescently tagged PRP19

• Quantification inconsistencies:

  • Problem: Nonlinear signal response across concentration ranges affects quantitative accuracy

  • Solution: Establish standard curves with recombinant protein; determine linear detection range; use internal calibrators for cross-experiment normalization

• Reproducibility challenges:

  • Problem: Batch-to-batch antibody variation compromises longitudinal studies

  • Solution: Procure single lots for extended studies; implement rigorous validation for new batches; maintain detailed records of antibody performance metrics

Addressing these pitfalls through careful experimental design and appropriate controls significantly enhances the reliability of PRP19A antibody-based research findings.

How do PRP19A antibodies contribute to understanding splicing dysregulation in cancer research?

PRP19A antibodies provide valuable tools for investigating the mechanisms of splicing dysregulation in cancer, offering insights into both fundamental disease biology and potential therapeutic interventions. PRP19, as a core component of the NineTeen Complex (NTC), plays critical roles in spliceosome activation and function, making it a key target for understanding cancer-associated splicing aberrations.

In cancer research applications, PRP19A antibodies enable several investigative approaches:

• Altered expression pattern analysis:

  • Immunohistochemical studies using PRP19A antibodies have revealed altered subcellular localization and expression levels across multiple cancer types

  • Nuclear accumulation of PRP19 correlates with advanced disease stages in several epithelial tumors

  • Antibody-based tissue microarray studies demonstrate that PRP19 overexpression associates with poor prognosis in colorectal and ovarian cancers

• Splicing complex integrity assessment:

  • Co-immunoprecipitation with PRP19A antibodies followed by mass spectrometry reveals cancer-specific alterations in NTC composition

  • These studies have identified loss of regulatory components in metastatic disease

  • Differential interaction patterns correlate with shifts toward pro-oncogenic splicing profiles

• Functional studies of splicing regulation:

  • Chromatin immunoprecipitation with PRP19A antibodies demonstrates altered recruitment to cancer-relevant genes

  • Immunofluorescence microscopy reveals disrupted nuclear speckle organization in malignant cells

  • Combined with RNA-seq approaches, these studies have mapped PRP19-dependent alternative splicing events in cancer progression

• Therapeutic response monitoring:

  • PRP19A antibody-based assays can measure changes in splicing complex composition following treatment with splicing-targeted therapeutics

  • Posttranslational modification-specific antibodies detect altered PRP19 phosphorylation states that correspond to treatment response

The reliability of antibodies significantly influences the correlation between mRNA and protein levels observed in tumor cohorts, underscoring the importance of using validated high-quality PRP19A antibodies in cancer research applications .

What are the considerations for using PRP19A antibodies in studying neurodegenerative disorders?

Using PRP19A antibodies in neurodegenerative disease research requires specialized considerations that address the unique challenges of neural tissue analysis. Emerging evidence suggests that splicing dysregulation contributes to multiple neurodegenerative conditions, positioning PRP19 as a relevant research target in this field.

Key considerations for neurodegenerative research applications include:

• Tissue-specific optimization:

  • Neural tissues require modified fixation protocols for optimal PRP19 epitope preservation

  • For immunohistochemistry in brain tissue, brief (8-10 hour) 4% PFA fixation followed by careful antigen retrieval (sodium citrate buffer, pH 6.0) provides superior results

  • PRP19A antibodies recognizing amino acids 127-416 typically perform well in fixed neural tissues due to epitope resilience during processing

• Cell type-specific expression assessment:

  • PRP19 expression varies across neural cell populations, necessitating co-staining with cell-type markers

  • Double immunofluorescence combining PRP19A antibodies with neuronal (NeuN), astrocytic (GFAP), or microglial (Iba1) markers allows cell type-specific analysis

  • Nuclear PRP19 levels in neurons correlate with transcriptional activity states, requiring careful interpretation

• Protein aggregation considerations:

  • Neurodegenerative diseases feature protein aggregation that can sequester or co-aggregate with splicing factors

  • When analyzing tissues with aggregation pathology, sequential extraction protocols are recommended:

    • RIPA-soluble fraction extraction

    • Followed by 2% SDS extraction for less soluble components

    • Final extraction with 8M urea for highly insoluble aggregates

  • Each fraction should be analyzed separately with PRP19A antibodies to detect potential sequestration

• Age-related and disease-specific modifications:

  • Phosphorylation patterns of PRP19 change with both aging and disease progression

  • Consider using phospho-specific antibodies alongside total PRP19 detection

  • Compare patterns between age-matched controls and disease samples to distinguish disease-specific changes from normal aging

• RNA processing analysis integration:

  • Combine PRP19A antibody-based protein analysis with RNA processing assessment

  • RNA-FISH for specific alternatively spliced transcripts relevant to neurodegeneration

  • Correlate PRP19 localization with RNA processing events in specific neural populations

These specialized considerations enhance the application of PRP19A antibodies in neurodegenerative research, allowing more accurate characterization of splicing alterations in conditions like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis .

How can researchers effectively use PRP19A antibodies to study DNA damage response pathways?

PRP19A antibodies serve as powerful tools for investigating DNA damage response (DDR) pathways, where PRP19 plays dual roles in coordinating both transcription-coupled repair and homologous recombination. Effectively studying these functions requires specialized experimental approaches:

• Damage-induced dynamics visualization:

  • PRP19 rapidly relocalizes to DNA damage sites following genotoxic stress

  • For effective immunofluorescence studies:

    • Pre-extract cells briefly (0.5% Triton X-100, 2 minutes) before fixation to remove soluble PRP19

    • This enhances visualization of damage-associated PRP19 foci

    • Co-stain with γH2AX to confirm localization to genuine damage sites

  • Live-cell imaging with fluorescently-tagged PRP19 complements antibody-based approaches

• Chromatin association analysis:

  • PRP19's recruitment to damaged chromatin can be effectively studied using:

    • Chromatin immunoprecipitation (ChIP) with PRP19A antibodies at defined damage sites

    • Biochemical fractionation followed by Western blotting to quantify chromatin-bound PRP19

    • For ChIP applications, crosslinking conditions must be optimized (1% formaldehyde, 10 minutes)

    • Sonication conditions should preserve protein complexes while fragmenting DNA

• DNA damage-specific interaction mapping:

  • PRP19 forms distinct protein complexes in response to different types of DNA damage

  • Immunoprecipitation with PRP19A antibodies followed by mass spectrometry reveals damage-specific interactomes

  • Compare interaction profiles across damage types:

    • UV irradiation (transcription-coupled repair)

    • Ionizing radiation (double-strand breaks)

    • Replication stress (stalled forks)

• Post-translational modification monitoring:

  • DNA damage triggers specific modifications of PRP19 that regulate its function

  • Phosphorylation at multiple sites modulates PRP19 activity in DDR

  • Use phospho-specific antibodies alongside total PRP19A antibodies to monitor activation state

  • For Western blotting applications, include phosphatase inhibitors (50mM NaF, 10mM Na₃VO₄) in extraction buffers

The following table summarizes optimal antibody selection for different DDR research applications:

By selecting appropriate antibodies and experimental approaches, researchers can effectively dissect PRP19's multifaceted roles in maintaining genome integrity through diverse DNA repair pathways .

How can multiparametric analysis with PRP19A antibodies advance understanding of splicing dynamics?

Multiparametric analysis incorporating PRP19A antibodies offers transformative approaches for investigating splicing dynamics with unprecedented resolution. By integrating antibody-based detection with complementary technologies, researchers can achieve multidimensional insights into splicing regulation across diverse biological contexts.

Advanced multiparametric strategies include:

• Multiplexed immunofluorescence approaches:

  • Combining PRP19A antibodies with antibodies against other spliceosome components enables visualization of complete splicing complex assembly

  • Cyclic immunofluorescence (CycIF) methods allow sequential staining with up to 40 antibodies on the same sample

  • This approach reveals spatial relationships between PRP19 and other factors across the nucleus

  • Quantitative image analysis provides compositional information at the single-cell level

• Single-cell multi-omics integration:

  • CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) allows simultaneous measurement of PRP19 protein levels and transcriptome-wide splicing patterns

  • PRP19A antibodies conjugated to DNA barcodes enable protein quantification alongside RNA analysis

  • This approach reveals correlations between PRP19 levels and specific splicing events at single-cell resolution

  • Data integration identifies cell populations with distinct splicing regulatory states

• Live-cell splicing dynamics visualization:

  • Antibody-derived nanobodies against PRP19 can be expressed as fluorescent fusions in living cells

  • When combined with fluorescently labeled pre-mRNA reporters, this enables real-time visualization of splicing dynamics

  • FRAP (Fluorescence Recovery After Photobleaching) with these tools measures PRP19 kinetics at active splicing sites

  • Correlative light and electron microscopy connects molecular-scale events to nuclear ultrastructure

• Proximity-dependent labeling applications:

  • PRP19A antibodies can be conjugated to enzymes like APEX2 or TurboID

  • When introduced into permeabilized cells, these conjugates catalyze biotinylation of proteins in close proximity to PRP19

  • Mass spectrometry analysis of biotinylated proteins reveals the dynamic "neighborhood" of PRP19 under different conditions

  • This approach identifies transient interactions missed by conventional co-immunoprecipitation

These multiparametric approaches generate multidimensional datasets that, when integrated through computational methods, provide systems-level understanding of how PRP19 coordinates splicing across cellular states and environmental conditions .

What are the emerging applications of PRP19A antibodies in studying RNA-protein interactions?

PRP19A antibodies are increasingly being applied to investigate complex RNA-protein interactions through emerging methodologies that combine antibody specificity with advanced RNA detection techniques. These innovative approaches are expanding our understanding of PRP19's role in RNA processing beyond conventional applications.

Cutting-edge applications include:

• Enhanced CLIP (Crosslinking and Immunoprecipitation) technologies:

  • PRP19A antibodies can be employed in iCLIP (individual-nucleotide resolution CLIP) to map RNA-binding sites with single-nucleotide precision

  • Optimization for PRP19 iCLIP includes:

    • UV crosslinking at 254nm (0.15 J/cm²) for protein-RNA interactions

    • Rigorous RNase titration to achieve optimal fragment length

    • High-salt washes (500mM NaCl) to reduce background

  • This approach has revealed direct RNA contacts of PRP19 at exon-intron boundaries and near branch points

• RNA-protein proximity mapping in intact cells:

  • APEX-mediated proximity labeling combined with PRP19A antibody immunoprecipitation

  • Cells expressing APEX2-tagged RNA-binding proteins are treated with biotin-phenol

  • After brief H₂O₂ exposure, proteins near specific RNAs become biotinylated

  • PRP19A antibody immunoprecipitation followed by biotin detection reveals RNA-proximal PRP19 populations

• RNA structure-dependent interaction analysis:

  • PRP19A antibodies can be used in structure-specific crosslinking studies

  • RNA structure-selective crosslinkers (e.g., psoralen for double-stranded regions)

  • Followed by PRP19 immunoprecipitation and high-throughput sequencing

  • This reveals how RNA secondary structures influence PRP19 recruitment and function

• Dynamic RNA processing visualization:

  • PRP19A antibodies in combination with RNA-FISH (Fluorescence In Situ Hybridization)

  • MS2-tagged pre-mRNAs allow simultaneous visualization of specific transcripts and PRP19

  • Time-resolved imaging captures the dynamics of PRP19 recruitment during splicing

  • Quantitative analysis measures residence time and stoichiometry at individual transcription sites

The following table summarizes these emerging applications:

These emerging applications are revealing unprecedented details about how PRP19 recognizes and processes RNA targets in diverse cellular contexts .

How might antibody engineering improve the utility of PRP19A antibodies in future research applications?

Antibody engineering presents promising avenues for enhancing PRP19A antibody utility across diverse research applications. Advanced engineering approaches can address current limitations while expanding functional capabilities for investigating PRP19 biology with unprecedented precision.

Future-oriented antibody engineering strategies include:

• Single-domain antibody (nanobody) development:

  • Camelid-derived single-domain antibodies against PRP19 epitopes offer several advantages:

    • Smaller size (~15kDa) enables access to sterically restricted epitopes

    • Superior penetration in tissue sections and live cells

    • Reduced interference with protein-protein interactions

  • Applications include super-resolution microscopy of nuclear PRP19 organization and intravital imaging of splicing dynamics

• Epitope-specific recombinant antibody libraries:

  • Phage display libraries designed against specific functional domains of PRP19:

    • U-box domain-specific antibodies to monitor ubiquitin ligase activity

    • WD40 repeat-specific antibodies that distinguish between different binding states

    • Conformational epitope antibodies that detect activation-specific states

  • These would enable functional rather than merely structural analysis of PRP19

• Conformation-sensitive antibody development:

  • Engineered antibodies that specifically recognize distinct conformational states of PRP19:

    • Active versus inactive forms in splicing complexes

    • DNA damage-responsive conformations

    • Ubiquitylation-associated structural changes

  • Such antibodies would serve as real-time sensors of PRP19 functional states in living systems

• Multifunctional antibody conjugates:

  • PRP19A antibodies conjugated to complementary functional moieties:

    • Proximity-dependent labeling enzymes (APEX2, TurboID) for spatially-resolved proteomics

    • RNA-modifying enzymes for targeted manipulation of PRP19-associated transcripts

    • Optogenetic domains for light-controlled perturbation of PRP19 function

  • These tools would enable not only observation but also controlled manipulation of PRP19 activities

• Enhanced biophysical properties:

  • Engineering stability-optimized variants for challenging experimental conditions:

    • Heat-stable versions for elevated temperature applications

    • Fixation-resistant epitope recognition for improved histological studies

    • Extended shelf-life for longitudinal studies

  • These improvements would enhance reproducibility across diverse experimental platforms

Key advances would be particularly valuable for resolving outstanding questions about PRP19's dynamic roles in coordinating RNA processing with genome maintenance and protein turnover. The development of these next-generation antibody tools requires interdisciplinary collaboration between structural biologists, protein engineers, and RNA processing experts, but would significantly accelerate research in this complex field .